FORMULATION AND CHARACTERIZATION OF LINEZOLID LOADED EUDRAGIT RS 100 POLYMERIC NANOPARTICLESAbstract
Tuberculosis (TB) is an alluring affliction caused predominantly by Mycobacterium tuberculosis bacteria. A stumbling block in the conventional treatment of TB is the occurrence of multiple drug resistance (MDR) followed by high dose requirement, subsequent intolerance & severe toxicity. Nanoparticulate-based drug therapy has significant potency in the treatment of TB. In this present study, Linezolid loaded Eudragit RS 100 polymeric nanoparticles (LZD-PNPs) were developed and characterised for the treatment of TB. Double emulsion solvent evaporation method was selected to incorporate LZD into Eudragit RS 100. Differential scanning calorimetry (DSC), Fourier Transfer Infrared spectroscopy (FT-IR) studies were done to assess drug-polymer compatibility and to indicate absence of incompatibility. Particle size analysis was carried out to measure the mean particle size of the LZD-PNPs and was found to be at 47nm-119nm (±26 to 41 SD) which indicated the polydispersity of the formulation. Zeta potential analysis of the sample was found to be -32 to -41mv, indicating its physicochemical stability. The Entrapment efficiency of LZD-PNPs ranged between 75.56% to 80.42%. Optimization of the LZD-PNPs was done by response surface analysis (Design Expert 184.108.40.206 software State Ease, Inc., Minneapolis, MN). The above data suggest that linezolid loaded Eudragit RS 100 polymeric nanoparticle were successfully formulated by double emulsion solvent evaporation method and characterized for effective delivery of MDR-TB.
J. Shaji * and M. Kumbhar
Department of Pharmaceutics, Prin. K. M. Kundnani College of Pharmacy, Cuffe Parde, Colaba, Mumbai, Maharashtra, India.
07 August 2018
23 October 2018
09 March 2019
01 April 2019